Journal List > Tuberc Respir Dis > v.62(2) > 1001052

TOOLS
Huh, Jegal, Hong, Oh, Shim, Lim, Lee, Kim, Kim, Kim, and Koh: Efficacy of deferoxamine on paraquat poisoning
Original Article
Tuberculosis and Respiratory Diseases

Tuberculosis and Respiratory Diseases 2007; 62(2): 113-118.

Published online: 28 February 2007

DOI: https://doi.org/10.4046/trd.2007.62.2.113

Efficacy of deferoxamine on paraquat poisoning

Jin Won Huh, M.D.1, Yangjin Jegal, M.D.2, Sang-Bum Hong, M.D.3, Yeon Mok Oh, M.D.3, Tae Sun Shim, M.D.3, Chae-Man Lim, M.D.3, Sang Do Lee, M.D.3, Woo Sung Kim, M.D.3, Dong Soon Kim, M.D.3, Won Dong Kim, M.D.3, Younsuck Koh, M.D.3

1Department of Internal Medicine Inje University, Korea.

2Department of Internal Medicine University of Ulsan, Korea.

3Division of Pulmonary and Critical Care Medicine, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea.

Address for correspondence: Younsuck Koh, M.D. Division of Pulmonary & Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine 388-1 Pungnap Dong, Songpa Ku, Seoul, 138-736, Korea. Phone: 02-3010-3134, Fax: 02-3010-6968, yskoh@amc.seoul.kr

Received 26 October 2006       Accepted 18 January 2007

Copyright © 2007 The Korean Academy of Tuberculosis and Respiratory Diseases

Abstract

Background

Paraquat is known to induce oxidant injury that results in multiorgan failure and lung fibrosis. Iron has been considered to play a key role in paraquat-induced oxidant lung injury. This study examined the effect of deferoxamine, an iron-chelating agent, in the treatment of paraquat poisoning.

Methods

From September, 2001 to April, 2005, 28 patients with paraquat poisoning who were admitted at a medical intensive care unit of a University-affiliated hospital, were enrolled in this study. Sixteen patients were treated according to the paraquat poisoning treatment guidelines and 12 received an intravenous infusion of deferoxamine in addition to the treatment guidelines.

Results

There were no differences between the two groups in terms of age, gender, severity of paraquat poisoning, and the time elapsed from ingestion to presentation at hospital. There was no difference in overall mortality between the two groups but the incidence of respiratory failure in the deferoxamine group was higher than in the conventional group(4/7 versus 0/9, p=0.019).

Conclusion

Deferoxamine seems to have no clinical benefit compared with the conventional treatment.

Keywords: Paraquat, Deferoxamine, Mortality

Figures and Tables

Table 1
AMC paraquat intoxication treatment protocol
trd-62-113-i001

Pd†: prednisolone, NO‡: nitric oxide, PFR*: PaO2/FiO2

Table 2
Initial clinical characteristics of patients at admission depending on deferoxamine therapy
trd-62-113-i002

MOF†: multiple organ falune

Table 3
Laboratory data of patients at the initial and the worst time.
trd-62-113-i003
Table 4
Clinical characteristics of nonsurvivors between the two groups
trd-62-113-i004

MOF†: multiple organ failune

Appendix 1
Brussels table of organ dysfunction
trd-62-113-a001

References

1. Hwang KY, Lee EY, Hong SY. Paraquat intoxication in Korea. Arch Environ Health. 2002. 57:162–166.
2. Suzuki K, Takasu N, Okabe T, Ishimatsu S, Ueda A, Tanaka S, et al. Effect of aggressive haemoperfusion on the clinical course of patients with paraquat poisoning. Hum Exp Toxicol. 1993. 12:323–327.
3. Koo JR, Kim JC, Yoon JW, Kim GH, Jeon RW, Kim HJ, et al. Failure of continuous venovenous hemofiltration to prevent death in paraquat poisoning. Am J Kidney Dis. 2002. 39:55–59.
4. Fock KM. Clinical features and prognosis of paraquat poisoning: a review of 27 cases. Singapore Med J. 1987. 28:53–56.
5. Suzuki K, Takasu N, Arita S, Maenosono A, Ishimatsu S, Nishina M, et al. A new method for predicting the outcome and survival period in paraquat poisoning. Hum Toxicol. 1989. 8:33–38.
6. Addo E, Ramdial S, Poon-King T. High dosage cyclophosphamide and dexamethasone treatment of paraquat poisoning with 75% survival. West Indian Med J. 1984. 33:220–226.
7. Addo E, Poon-King T. Leucocyte suppression in treatment of 72 patients with paraquat poisoning. Lancet. 1986. 1:1117–1120.
8. Perriens JH, Benimadho S, Kiauw IL, Wisse J, Chee H. High-dose cyclophosphamide and dexamethasone in paraquat poisoning: a prospective study. Hum Exp Toxicol. 1992. 11:129–134.
9. Lin JL, Wei MC, Liu YC. Pulse therapy with cyclophosphamide and methylprednisolone in patients with moderate to severe paraquat poisoning: a preliminary report. Thorax. 1996. 51:661–663.
10. Lin JL, Leu ML, Liu YC, Chen GH. A prospective clinical trial of pulse therapy with glucocorticoid and cyclophosphamide in moderate to severe paraquat-poisoned patients. Am J Respir Crit Care Med. 1999. 159:357–360.
11. Lheureux P, Leduc D, Vanbinst R, Askenasi R. Survival in a case of massive paraquat ingestion. Chest. 1995. 107:285–289.
12. Hershko C, Weatherall DJ. Iron-chelating therapy. Crit Rev Clin Lab Sci. 1988. 26:303–345.
13. van Asbeck BS, Hillen FC, Boonen HC, de Jong Y, Dormans JA, van der Wal NA, et al. Continuous intravenous infusion of deferoxamine reduces mortality by paraquat in vitamin E-deficient rats. Am Rev Respir Dis. 1989. 139:769–773.
14. van der Wal NA, van Oirschot JF, van Dijk A, Verhoef J, van Asbeck BS. Mechanism of protection of alveolar type II cells against paraquat-induced cytotoxicity by deferoxamine. Biochem Pharmacol. 1990. 39:1665–1671.
15. van der Wal NA, Smith LL, van Oirschot JF, van Asbeck BS. Effect of iron chelators on paraquat toxicity in rats and alveolar type II cells. Am Rev Respir Dis. 1992. 145:180–186.
16. Proudfoot AT, Stewart MS, Levitt T, Widdop B. Paraquat poisoning: significance of plasma-paraquat concentrations. Lancet. 1979. 2:330–332.
17. Tsatsakis AM, Perakis K, Koumantakis E. Experience with acute paraquat poisoning in Crete. Vet Hum Toxicol. 1996. 38:113–117.
18. Huh JW, Hong SB, Lim CM, Do KH, Lee JS, Koh Y. Sequential radiologic and functional pulmonary changes in patients with paraquat intoxication. Int J Occup Environ Health. 2006. 12:203–208.
19. Hong SY, Yang DH, Hwang KY. Associations between laboratory parameters and outcome of paraquat poisoning. Toxicol Lett. 2000. 118:53–59.
20. Kohen R, Chevion M. Paraquat toxicity is enhanced by iron and reduced by desferrioxamine in laboratory mice. Biochem Pharmacol. 1985. 34:1841–1843.
21. Poot M, Rabinovitch PS, Hoehn H. Free radical mediated cytotoxicity of desferrioxamine. Free Radic Res Commun. 1989. 6:323–328.
22. Osheroff MR, Schaich KM, Drew RT, Borg DC. Failure of desferrioxamine to modify the toxicity of paraquat in rats. J Free Radic Biol Med. 1985. 1:71–82.
23. Tenenbein M, Kowalski S, Sienko A, Bowden DH, Adamson IY. Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning. Lancet. 1992. 339:699–701.
24. Buettner GR, Jurkiewicz BA. Catalytic metals, ascorbate and free radicals: combinations to avoid. Radiat Res. 1996. 145:532–541.
25. Carr A, Frei B. Does vitamin C act as a pro-oxidant under physiological conditions? FASEB J. 1999. 13:1007–1024.
26. Kang SA, Jang YJ, Park H. In vivo dual effects of vitamin C on paraquat-induced lung damage: dependence on released metals from the damaged tissue. Free Radic Res. 1998. 28:93–107.
TOOLS
Similar articles